<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37202026</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2214-109X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet. Global health</Title><ISOAbbreviation>Lancet Glob Health</ISOAbbreviation></Journal><ArticleTitle>Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey.</ArticleTitle><Pagination><StartPage>e917</StartPage><EndPage>e923</EndPage><MedlinePgn>e917-e923</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2214-109X(23)00116-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2214-109X(23)00116-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Novel oral poliovirus vaccine type 2 (nOPV2) was administered in Liberia in response to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in 2021. We conducted a serological survey of polio antibodies after two national campaigns with nOPV2.</AbstractText><AbstractText Label="METHODS">This clustered, cross-sectional, population-based seroprevalence survey was conducted in children aged 0-59 months, more than 4 weeks after the second nOPV2 vaccination round. We used a clustered sampling method in four geographical regions of Liberia, followed by a simple random sampling of households. One eligible child was randomly selected per household. Dried blood spot specimens were taken and vaccination history was recorded. The antibody titres against all three poliovirus serotypes were assessed using standard microneutralisation assays done at the US Centers for Disease Control and Prevention in Atlanta, GA, USA.</AbstractText><AbstractText Label="FINDINGS">Analysable data were obtained from 436 (87%) of 500 enrolled participants. Of these, 371 (85%) children were reported via parental recall to have received two nOPV2 doses, 43 (10%) received one dose, and 22 (5%) received no doses. The seroprevalence against type 2 poliovirus was 38·3% (95% CI 33·7-43·0; 167 of 436 participants). No significant difference was observed between type 2 seroprevalence in children aged 6 months or older who were reported to have received two doses of nOPV2 (42·1%, 95% CI 36·8-47·5; 144 of 342), one dose (28·0%, 12·1-49·4; seven of 25), or no doses (37·5%, 8·5-75·5; three of eight; p=0·39). The seroprevalence against type 1 was 59·6% (54·9-64·3; 260 of 436), and the seroprevalence against type 3 was 53·0% (48·2-57·7; 231 of 436).</AbstractText><AbstractText Label="INTERPRETATION">Unexpectedly, the data showed low type 2 seroprevalence after two reported doses of nOPV2. This finding is probably affected by the lower oral poliovirus vaccine immunogenicity previously demonstrated in resource-limited settings, with high prevalence of chronic intestinal infections in children and other factors discussed herein. Our results provide the first assessment of nOPV2 performance in outbreak response in the African region.</AbstractText><AbstractText Label="FUNDING">WHO and Rotary International.</AbstractText><CopyrightInformation>Copyright © 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved. This is an Open Access article published under the CC BY NC ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>University of Liberia-Pacific Institute for Research &amp; Evaluation (UL-PIRE) Africa Center, University of Liberia, Monrovia, Liberia; West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP), Monrovia, Liberia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Grace R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organization, Geneva, Switzerland. Electronic address: mackling@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason Ross</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Liberia-Pacific Institute for Research &amp; Evaluation (UL-PIRE) Africa Center, University of Liberia, Monrovia, Liberia; West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP), Monrovia, Liberia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Cavestany</LastName><ForeName>Rocio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moukom</LastName><ForeName>Richelot A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>World Health Organisation African Regional Office, Brazzaville, Republic of the Congo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Kathryn A V</ForeName><Initials>KAV</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massaquoi</LastName><ForeName>Moses B F</ForeName><Initials>MBF</Initials><AffiliationInfo><Affiliation>West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP), Monrovia, Liberia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kieh</LastName><ForeName>Mark W S</ForeName><Initials>MWS</Initials><AffiliationInfo><Affiliation>West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP), Monrovia, Liberia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Glob Health</MedlineTA><NlmUniqueID>101613665</NlmUniqueID><ISSNLinking>2214-109X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Glob Health. 2023 Jun;11(6):e811-e812. doi: 10.1016/S2214-109X(23)00161-4</RefSource><PMID Version="1">37202011</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007988" MajorTopicYN="N" Type="Geographic">Liberia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>20</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37202026</ArticleId><ArticleId IdType="pmc">PMC10187988</ArticleId><ArticleId IdType="doi">10.1016/S2214-109X(23)00116-X</ArticleId><ArticleId IdType="pii">S2214-109X(23)00116-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Africa Regional Commission for the Certification of Poliomyelitis Eradication Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world. Lancet Glob Health. 2020;8:e1345–e1351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525084</ArticleId><ArticleId IdType="pubmed">32916086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl 1):S283–S293.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2020–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1691–1699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Global Eradication Initiative  Global circulating vaccine-derived poliovirus (cVDPV) as of 04 April 2023. April 4, 2023. https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/</Citation></Reference><Reference><Citation>WHO . World Health Organization; Geneva: 2022. Statement of the thirty-first polio IHR Emergency Committee [press release March 11, 2022]</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934–938.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O'Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . World Health Organisation; Switzerland: 2021. Recommendation for an Emergency Use Listing (EUL) of novel oral polio vaccine type 2 (nOPV2) submitted by PT BioFarma (Persero)https://extranet.who.int/pqweb/sites/default/files/documents/nOPV2_EUL_recommendation.pdf</Citation></Reference><Reference><Citation>Te Ye M, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736–751. e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Tevi-Benissan C, Okeibunor J, du Chatellier GM, et al. Introduction of inactivated poliovirus vaccine and trivalent oral polio vaccine/bivalent oral polio vaccine switch in the African region. J Infect Dis. 2017;216(suppl 1):S66–S75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853502</ArticleId><ArticleId IdType="pubmed">28838178</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145–176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . World Health Organization; 2018. World Health Organization vaccination coverage cluster surveys: reference manual.</Citation></Reference><Reference><Citation>Saez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397:27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397:39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzoev A, Macklin GR, Zhang Y, et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Lancet Glob Health. 2022;10:e1807–e1814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9681660</ArticleId><ArticleId IdType="pubmed">36400086</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC. Immunogenicity and effectiveness of routine immunisation with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis. 2014;210(suppl 1):S439–S446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach O, Verma H, Khandait DW, et al. Prevalence of asymptomatic poliovirus infection in older children and adults in northern India: analysis of contact and enhanced community surveillance, 2009. J Infect Dis. 2014;210(suppl 1):S252–S258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4663665</ArticleId><ArticleId IdType="pubmed">25316843</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri F, Bhuiyan TR, Sack DA, Svennerholm AM. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine. 2013;31:452–460.</Citation><ArticleIdList><ArticleId IdType="pubmed">23153448</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker EP, Kampmann B, Kang G, Grassly NC. Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis. J Infect Dis. 2014;210:853–864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4136801</ArticleId><ArticleId IdType="pubmed">24688069</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13:926–939.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles M, Ryman TK, Dietz V, Zell E, Luman ET. Validity of vaccination cards and parental recall to estimate vaccination coverage: a systematic review of the literature. Vaccine. 2013;31:1560–1568.</Citation><ArticleIdList><ArticleId IdType="pubmed">23196207</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . World Health Organization; Geneva: 2022. Standard operating procedures: responding to a poliovirus event or outbreak.</Citation></Reference><Reference><Citation>WHO  WHO/UNICEF Joint Reporting Form on Immunisation (JRF) 2021. https://www.who.int/data/immunization</Citation></Reference><Reference><Citation>Endegue MC, Sein C, Cavestany RL, et al. Community-based survey to assess seroprevalence of poliovirus antibodies in far-north Cameroon in 2020. Vaccine X. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9763508</ArticleId><ArticleId IdType="pubmed">36560978</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamougam K, Jeyaseelan V, Jones KA, et al. A survey to assess serological prevalence of poliovirus antibodies in areas with high-risk for vaccine-derived poliovirus transmission in Chad. J Pediatric Infect Dis Soc. 2022;11:55–59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865003</ArticleId><ArticleId IdType="pubmed">34791366</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>